Nettleship JE - Search Results

1

Testosterone and atherosclerosis in aging men: purported association and clinical implications.

Jones RD, Nettleship JE, Kapoor D, Jones HT, Channer KS. Jones RD, et al. Among authors: nettleship je. Am J Cardiovasc Drugs. 2005;5(3):141-54. doi: 10.2165/00129784-200505030-00001. Am J Cardiovasc Drugs. 2005. PMID: 15901202 Review.

2

Effects of continuous long-term testosterone therapy (TTh) on anthropometric, endocrine and metabolic parameters for up to 10 years in 115 hypogonadal elderly men: real-life experience from an observational registry study.

Yassin AA, Nettleship J, Almehmadi Y, Salman M, Saad F. Yassin AA, et al. Andrologia. 2016 Sep;48(7):793-9. doi: 10.1111/and.12514. Epub 2016 Jan 14. Andrologia. 2016. PMID: 26762680

3

Inverse relationship between serum levels of interleukin-1beta and testosterone in men with stable coronary artery disease.

Nettleship JE, Pugh PJ, Channer KS, Jones T, Jones RD. Nettleship JE, et al. Horm Metab Res. 2007 May;39(5):366-71. doi: 10.1055/s-2007-976543. Horm Metab Res. 2007. PMID: 17533579

4

Testosterone suppresses the expression of regulatory enzymes of fatty acid synthesis and protects against hepatic steatosis in cholesterol-fed androgen deficient mice.

Kelly DM, Nettleship JE, Akhtar S, Muraleedharan V, Sellers DJ, Brooke JC, McLaren DS, Channer KS, Jones TH. Kelly DM, et al. Among authors: nettleship je. Life Sci. 2014 Jul 30;109(2):95-103. doi: 10.1016/j.lfs.2014.06.007. Epub 2014 Jun 20. Life Sci. 2014. PMID: 24953607

5

Testosterone and coronary artery disease.

Nettleship J, Jones R, Channer K, Jones T. Nettleship J, et al. Front Horm Res. 2009;37:91-107. doi: 10.1159/000176047. Front Horm Res. 2009. PMID: 19011291 Review.

6

Physiological testosterone replacement therapy attenuates fatty streak formation and improves high-density lipoprotein cholesterol in the Tfm mouse: an effect that is independent of the classic androgen receptor.

Nettleship JE, Jones TH, Channer KS, Jones RD. Nettleship JE, et al. Circulation. 2007 Nov 20;116(21):2427-34. doi: 10.1161/CIRCULATIONAHA.107.708768. Epub 2007 Nov 5. Circulation. 2007. PMID: 17984376

7

Physiologic testosterone therapy has no effect on serum levels of tumour necrosis factor-alpha in men with chronic heart failure.

Pugh PJ, Jones RD, Malkin CJ, Hall J, Nettleship JE, Kerry KE, Jones TH, Channer KS. Pugh PJ, et al. Among authors: nettleship je. Endocr Res. 2005;31(4):271-83. doi: 10.1080/07435800500406205. Endocr Res. 2005. PMID: 16433247 Clinical Trial.

8

Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters.

Yassin A, Nettleship JE, Talib RA, Almehmadi Y, Doros G. Yassin A, et al. Among authors: nettleship je. Aging Male. 2016;19(1):64-9. doi: 10.3109/13685538.2015.1126573. Epub 2016 Jan 8. Aging Male. 2016. PMID: 26742589

9

Early weight loss predicts the reduction of obesity in men with erectile dysfunction and hypogonadism undergoing long-term testosterone replacement therapy.

Salman M, Yassin DJ, Shoukfeh H, Nettleship JE, Yassin A. Salman M, et al. Among authors: nettleship je. Aging Male. 2017 Mar;20(1):45-48. doi: 10.1080/13685538.2016.1260107. Epub 2017 Jan 13. Aging Male. 2017. PMID: 28084147

10

Waist circumference is superior to weight and BMI in predicting sexual symptoms, voiding symptoms and psychosomatic symptoms in men with hypogonadism and erectile dysfunction.

Yassin AA, Nettleship JE, Salman M, Almehmadi Y. Yassin AA, et al. Among authors: nettleship je. Andrologia. 2017 May;49(4). doi: 10.1111/and.12634. Epub 2016 Jul 12. Andrologia. 2017. PMID: 27400881

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results